Another question that remains so far unanswered is whether the association of tumor-peptide vaccination combined with a stronger adjuvant after adoptive cell transfer would induce a more sustained anti-tumor specific CD8 T-cell expansion and potentially counterbalance the homeostatic proliferation of Tregs in vivo. The gene discussed is CD8A; the disease is neoplasm.